



Transparency Declaration

-

Disclosure of Payments Made by Chugai Across Europe in 2023

Published June 2024

Chugai Pharma Europe Ltd.

Introduction and Background

Chugai Pharma Europe Ltd and Chugai Pharmaceutical Co. Ltd, Japan disclose all relevant transfers of value to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) made in the European Union in accordance with the EFPIA Disclosure Code¹ and the relevant local Codes of Practice and/or local legal requirements, and also in accordance with Data Protection regulations (including but not limited to the General Data Protection Regulation (GDPR) (EU) 2016/679 and local legislation)².

The move towards greater transparency is part of a Europe-wide initiative designed to bring clarity and transparency to the manner in which the research based pharmaceutical industry and the healthcare community collaborate, which ultimately have been shown to benefit patient care. The HCP offers invaluable expertise on disease management and plays an important part in informing the pharmaceutical industry's efforts to improve patient care and treatment – both critical to improving health outcomes. It's important that these interactions meet the highest standard of integrity that patients, governments, regulatory bodies, other stakeholders and the media expect. Our goal is to assure the public that such relationships do not influence clinical decisions and that they can trust their HCP to recommend treatment, or administer appropriate care based solely on clinical evidence and experience.

Chugai Pharma Europe Ltd and Chugai Pharmaceutical Co. Ltd, Japan support the initiative by The European Federation of Pharmaceutical Industries and Associations (EFPIA) (<https://www.efpia.eu/>) and has taken the decision to disclose all transfers of value in keeping with the EFPIA Code on Disclosure on Transfers of Value to Pharmaceutical Companies to HCPs and HCOs (<https://www.efpia.eu/relationshipscode/disclosure-of-payments/>) for both direct and indirect payments made across the European Union from any part of the Chugai corporation. Furthermore, some payments will be disclosed by Chugai Pharma Europe to other European countries not within the European Union.

The local payments in those countries where there is a Chugai affiliate business then these are disclosed via central platforms in France, Germany and the UK respectively in accordance with local Code requirements:

- Chugai Pharma UK disclose in accordance with both The Association of British Pharmaceutical Industry (ABPI)³ and the Irish Pharmaceutical Healthcare Association (IPHA)⁴ as the company undertakes marketing activities in both Member States.
- Chugai Pharma France disclose in accordance with Loi Bertrand via the website Ordre National Des Medecins⁵.
- Chugai Pharma Germany disclose in accordance with the Code of Conduct of the members of Verein Arzneimittel und Kooperation im Gesundheitswesen e.V. ("AKG")⁶.

- Chugai Pharmaceutical Co. Ltd, Japan disclose in accordance with The Japan Pharmaceutical Manufacturers Association (JPMA) Code of Practice⁷.
- Payments made in the United States are disclose in accordance with The Physician Financial Transparency Report (‘Sunshine Act’) managed by Genentech⁸.

Chugai Pharma Europe Ltd and Chugai Pharmaceutical Co. Ltd, Japan have also taken the initiative to disclose all transfers of value relating to those HCPs and HCOs who are registered to practice in European countries where there is no Chugai office or marketing activities. Direct payments take place where a HCP has provided consultative support with regards to product development in order to give a better understanding of local treatment and regulatory needs. For these engagements there is a contract containing clearly defined consultative role in content, context and format and any payment would be strictly controlled through standard Fair Market Value limitations⁹. Such engagements would include attendance to advisory boards meetings or speaking at a company-sponsored event. Indirect payments take place during the research and development phase where responsibility for managing a clinical trial has been outsourced to a Clinical Research Organisation (CRO). The CRO are responsible for making these payments, and Chugai is responsible for ensuring such indirect payments are disclosed accurately. Payments relating to research and development are to be disclosed in an aggregated form in accordance with EFPIA requirements:

- Research and Development ToV. Research and Development ToVs in each Reporting Period must be disclosed by each Member Company on an aggregate basis.
- Costs related to Events that are clearly related to activities covered in this section can be included in the aggregate amount under the “Research and Development Transfers of Value” category.

Payments relating to activities that do not fit the criteria of research and development are disclosed at an individual level. Payments made by Chugai Pharma Europe Ltd and Chugai Pharmaceutical Co. Japan will also be made in the non R&D setting where a therapy area specialist may be invited to provide advice at an advisory board or attend a company-sponsored event as a speaker.

In most EU Member States explicit consent is a fundamental requirement in order to disclose at a named individual level which captures payments relating to:

- the contribution of costs related to events (e.g. travel, accommodation) and includes sponsorship
- fees for service and consultancy.

Chugai upholds and works according to The General Data Protection Regulation 2016/679 (GDPR). Where explicit consent is not given then the transfer of value will be disclosed in an aggregated form.

Chugai encourages all transfers of value to be disclosed in a form that is transparent and will disclose according to the requirements of each Member State.

Payments made to Healthcare Organisations are all disclosed at a named institutional level.

The disclosed payments are in local currency where possible. The information given relates to payments made in the financial year Jan 1st, 2023 to Dec 31st, 2023 and relates to the dates of payments rather than event dates.

The EFPIA Code requires disclosure in the country where the Recipient has its principal practice. All Transfers of Value to a given recipient will be disclosed in the country where this principal practice is located.

The EFPIA Code states that each Member Company will decide how to organise its disclosures, either at a central or local level, unless the national code fixes the platform of disclosure. However, disclosure should conform to the national code requirements and relevant disclosures should be publicly accessible in the country where the Recipient has their practice. If a Member Company is not resident or does not have a subsidiary or an affiliate in the country where the Recipient has their principal practice, the Member Company should disclose the Transfer of Value in a manner consistent with the national code of the country where the Recipient has their practice. This information will be publicly available for 3 (three) years and stored for a minimum of 5 (five) years. Chugai does not support partial disclosure. Chugai supports these initiatives and will adhere to the relevant Codes of Practice.

This is a progressive initiative with the objective for Chugai to disclose all transfers of value in a format which is in accordance with local requirements (using the standard template).

Chugai is not a direct member of EFPIA and does not have a business office in every country so is not required to disclose in every country. Chugai is doing so in the spirit of transparency.

Please note that currency conversion rates may result in disclosed figures being slightly different. To discuss anything further please contact disclosure@chugai-pharm.co.uk

Head of Compliance

Chugai Pharma Europe Ltd

References:

1. EFPIA Code on Disclosure on Transfers of Value to Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations
(www.efpia.eu/relationships-code/disclosure-of-payments/)
2. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016R0679&qid=1719343340075>
3. www.abpi.org.uk/reputation/disclosure-uk/
4. www.transferofvalue.ie/
5. www.transparence.sante.gouv.fr/flow/main?execution=e2s1
6. www.ak-gesundheitswesen.de/?cn-reloaded=1
7. www.jpma.or.jp/english/
8. www.gene.com
9. www.efpia.eu/relationships-code/national-codes/

Payments Made in 2023

Payments were made to Healthcare Professionals and/or Healthcare Organisations in the below countries.

Click on the 'COUNTRY NAME' to access the disclosed payment details.

Click on 'Methodological notes' for full details of Chugai's disclosure methodology.

European Member States where Payments were made in 2023	Link to Chugai's methodological notes
Austria	Methodological notes
Belgium	
Czech Republic	
Italy	
Netherlands	
Norway	
Portugal	
Spain	
Sweden	
Switzerland	

Austria

1	PHARMIG CODE OF CONDUCT - GUIDANCE REGARDING ARTICLE 9 - STANDARDIZED DISCLOSURE TEMPLATE													
2														
3	DISCLOSURE TEMPLATE - ARTICLE 9 CoC (TRANSPARENCY)						Reporting period (calendar year): 2023 Date of publication: 30/06/2024							
4														
5		Full Name	Practice or business address			Where available: physician number commercial register number, association register number	Donations and Grants to HCOs	Contribution to costs of events <i>(cf. Article 9.4a 1) (i), (ii) CoC and/or Article 9.4b 2) (i), (ii), (iii) CoC)</i>			Fees for services and consultancy <i>(cf. Article 9.4a 2) CoC and/or Article 9.4b 3) CoC)</i>			TOTAL <i>Optional</i>
6		<i>(cf. Article 9.4 CoC)</i>	<i>(cf. Article 9.4 CoC)</i>	<i>(cf. Article 9.4 CoC)</i>	<i>(cf. Article 9.4 CoC)</i>	<i>(cf. Article 9.4 CoC)</i>		Support agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel & accomodation	Fees	Outlays		
7	HCPs	INDIVIDUAL NAMED DISCLOSURE FOR HEALTHCARE PROFESSIONALS <i>[one line per HCP, all transfers of value during a reporting period for an individual HCP will be summed up]</i>												
8		HCP 1					N/A	N/A	0	0	0	0	0	0
9		HCP 2					N/A	N/A	0	0	0	0	0	0
10		etc.					N/A	N/A	0	0	0	0	0	0
11		AGGREGATE DISCLOSURE FOR HEALTHCARE PROFESSIONALS												
12		Total amount					N/A	N/A	0	0	0	0	0	0
13		Total number of recipients of transfers of value by subtype					N/A	N/A	0	0	0	0	0	0
14		% of total transfers of value to all HCP recipients by subtype					N/A	N/A	0	0	0	0	0	0
15	HCOs	INDIVIDUAL NAMED DISCLOSURE FOR HEALTHCARE ORGANIZATIONS <i>[one row per HCO, all transfers of value during a reporting period for an individual HCO will be summed up]</i>												
16		HCO 1	MEDICAL UNIVERSITY OF VIENNA	Waehringer Guertel 18-20 A- 1090 Vienna, Austria			0	35000	0	0	0	0	0	35000
17		etc.					0	0	0	0	0	0	0	0
18		AGGREGATE DISCLOSURE FOR HEALTHCARE ORGANIZATIONS												
19			Total amount					0	0	0	0	0	0	0
20		Total number of recipients of transfers of value by subtype					0	0	0	0	0	0	0	0
21		% of total transfers of value to all HCO recipients by subtype					0	0	0	0	0	0	0	0
22	R & D	AGGREGATE DISCLOSURE FOR RESEARCH & DEVELOPMENT												
23		Transfers of value re Research & Development, cf. Article 9.3a CoC												2850
24	The rules referred to are those set out in the Pharmig Code of Conduct (CoC)													
25	HCP - healthcare professional within the meaning of Article 2.2 CoC													
26	HCO - healthcare establishment, organization or institution within the meaning of Article 2.2 CoC													
27	R&D - research and development													
28	The reporting period is the calendar year													

Belgium

Data Disclosure Form												Date of Publication: 30-06-2024	
HCPs	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country Identifier <small>OPTIONAL</small>	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy			Total Optional
							Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accomdation relevant to the contract		
INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
							0	0	0	0			0
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
Aggregate amount attributable to transfers of value to such Recipients								0	0	787.50	0		787.50
Number of Recipients in aggregate disclosure								0	0	1	0		0
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed								0 %	0	100%	0		0
INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
						0	0	0	0	0			0
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
Aggregate amount attributable to transfers of value to such Recipients						0	0	0	0	0	0		0
Number of Recipients in aggregate disclosure						0	0	0	0	0	0		0
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						0	0	0	0	0	0		0
AGGREGATE DISCLOSURE													
Transfers of Value re Research & Development as defined													0

Příloha 2 - ŠABLONA													
3	4	5	6	7	8	9	10	11	12	13	14	15	16
		Celé jméno	Zdravotnicko odborníci: místo výkonu hlavní praxe (obec), Zdravotnické zařízení: místo registrace (obec)	Stát výkonu hlavní praxe	Adresa hlavní praxe	Unikátní lokální identifikátor státu VOLITELNĚ	Dary a granty zdrav. zařízením (Čl. 3.01.1.a)	Příspěvky na náklady akcí (Čl. 3.01.1.b & 3.01.2.a)	Odměny za služby a konzultace (Čl. 3.01.1.c & 3.01.2.c)				
		(Odst. 1.01)	(Čl. 3)	(Příloha 1)	(Čl. 3)	(Čl. 3)		Smlouvy o sponzorování se zdrav. zařízeními / třetími stranami pověřenými zdrav. zařízeními pořádaním akce	Registrační poplatky	Doprava a ubytování	Platby/odměny	Platby nebo jiná plnění související s odměnou nebo sjednané v poradenské smlouvě včetně dopravy a ubytování příslušné k dané	CELKEM VOLITELNĚ
6													
7	Zdravotníci odborníci	UVEDENÍ JEDNOTLIVÝCH JMEN - každý zdrav. odborník na jeden řádek (tj. všechny platby nebo jiná plnění v průběhu roku na jednotlivého zdrav. odborníka budou sečteny: podle potřeby se předkládá položkový rozpis pouze pro potřebu jednotlivých příjemců nebo veřejných orgánů)											
8		MUDr. A					-	-	0	0	0	0	0
9		MUDr. B					-	-	0	0	0	0	0
10		atd.					-	-	0	0	0	0	0
11		OSTATNÍ, NEUVEDENO VÝŠE - pokud informace nelze vzhledem k právním předpisům zveřejnit individuálně											
12		Souhrnná částka připadající na platby nebo jiná plnění těmto příjemcům - Čl. 3.02					-	-	0	198878.5	80000	0	278878.5
13		Počet příjemců (případně jmenný seznam) - Čl. 3.02					-	-	0	1	1	0	1
14		% z celkových plateb nebo jiných plnění na jednotlivé zdrav. odborníky - Čl. 3.02					-	-	0	100%	100%	0	100%
15	Zdravotnická zařízení	UVEDENÍ JEDNOTLIVÝCH NÁZVŮ - každé zdrav. zařízení na jeden řádek (tj. všechny platby nebo jiná plnění v průběhu roku na jednotlivé											
16		Zdrav. zařízení 1					0	0	0	0	0	0	0
17		Zdrav. zařízení 2					0	0	0	0	0	0	0
18		atd.					0	0	0	0	0	0	0
19		OSTATNÍ, NEUVEDENO VÝŠE - pokud informace nelze vzhledem k právním předpisům zveřejnit individuálně											
20		Souhrnná částka připadající na platby nebo jiná plnění těmto příjemcům - Čl. 3.02					0	0	0	0	0	0	0
21		Počet příjemců (případně jmenný seznam) - Čl. 3.02					0	0	0	0	0	0	0
22		% z celkových plateb nebo jiných plnění na jednotlivé zdrav. zařízení - Čl. 3.02					0	0	0	0	0	0	0
23													
24	Výzkum a vývoj	SOUHRNNÉ ZVEŘEJNĚNÍ											
25		Platby a jiná plnění spojená s výzkumem a vývojem - Odstavec 3.04 and Příloha 1										0	0

Italy

Data Disclosure Form													
Date of Publication: 30-06-2024													
HCPs	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country Identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy			Total Optional
							Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	Luca Richeldi	Roma	Italy	Largo Agostino Gemelli 8, 00168 Roma				0		930.00	0		930.00
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients							0	0	0	0		0
	Number of Recipients in aggregate disclosure							0	0	0	0		0
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed							0	0	0	0		0	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	ADQI Consensus Conference	Vicenza	Italy	Viale Astichello, 6, 36100, Vicenza		0	20,000.00	0	0	0	0		20,000.00
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients					0	0	0	0	0	0		0
	Number of Recipients in aggregate disclosure					0	0	0	0	0	0		0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0	0	0	0	0	0		0
	AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined												1000.00	

Netherlands

EFPIA Disclosure Report – 2023 Data – Netherlands

Data disclosure form (Currency EUR)												2023 HCP/HCO Disclosure Date of publication: 30/06/2024	
	Full name	HCPs: City of Principal Practice HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier (OPTIONAL)	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		TOTAL (OPTIONAL)	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients								0.00	0.00	801.00	0.00	801.00
	Number of Recipients in aggregate disclosure								0	0	1	0	N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed								0%	0%	100%	0%	N/A
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients						0.00	0.00	0.00	0.00	0.00	0.00	Optional
	Number of Recipients in aggregate disclosure						0	0	0	0	0	0	N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						0%	0%	0%	0%	0%	0%	N/A
HCOs	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined											0.00	

Norway

Data Disclosure Form														
Date of Publication: 30-06-2024														
HCPs	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country Identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy			Total Optional	
							Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accomodation relevant to the contract			
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
								0	0	0	0		0	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients								0	0	0	0		0
	Number of Recipients in aggregate disclosure								0	0	0	0		0
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed								0	0	0	0		0	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
						0	0	0	0	0	0		0	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons													
	Aggregate amount attributable to transfers of value to such Recipients						0	0	0	0	0	0		0
	Number of Recipients in aggregate disclosure						0	0	0	0	0	0		0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						0	0	0	0	0	0		0
	AGGREGATE DISCLOSURE													
Transfers of Value re Research & Development as defined												108,704.58		

Portugal

Data Disclosure Form												
Date of Publication: 30-06-2024												
HCPs	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country Identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy		Total Optional
							Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accomodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accomodation relevant to the contract	
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
								0		0	0	0
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients							0	482.10	0	0	482.10
	Number of Recipients in aggregate disclosure							0	5	0	0	5
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed							0	100%	0	0	100%
HCO	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
						0	0	0	0	0	0	0
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients					0	0	0	0	0	0	0
	Number of Recipients in aggregate disclosure					0	0	0	0	0	0	0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0	0	0	0	0	0	0
AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined											0

	Full Name (Mandatory) (Art. 18.3)	Healthcare Professionals (HCPs): city of principal practice Healthcare Organisations (HCOs): city where registered (Art. 18.3)	Country of Principal Practice (Optional) (Art. 18.3)	Principal Practice Address (optional) (Art. 18.3)	DNI/CIF XX12345XX (Mandatory) (Art. 18.3)	Donations (Art.18.3.1. a)	Contribution to educational and scientific meetings (Art. 18.3.1.b & 18.3.2.a) (Art. 18.3.1.b & 18.3.2.a)			Fee for service (Art. 18.3.1.c & 18.3.2.b) (Art. 18.3.1.c & 18.3.2.b)		TOTAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodat ion	Fees	Related expenses agreed in the fee for service or consultan cy contract	
Healthcare Professionals (HCPs)	PUBLICACIÓN NOMINATIVA INDIVIDUAL: one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	Enriqueta Felip	Barcelona	Spain	Vall d'Hebron University Hospital				0	0		4,000.000	4,000.00
	Eva Maria Ciruelos Gil	Madrid	Spain	University Hospital Madrid				0	0		1,500.000	1,500.00
	Javier Cortes Castan	Madrid	Spain	University Hospital Madrid				0	0		2,400.00 0	2,400.00
	OTHER, NOT INCLUDED ABOVE — where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Article 18.4						N/A	N/A				
	Number of Recipients in aggregate disclosure - Article 18.4						N/A	N/A				
	Number of Recipients disclosed in aggregate as a % of all Recipients (individual & aggregate disclosures) - Article 18.4						N/A	N/A				
Healthcare Organisations (HCOs)	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
Research and Development	AGGREGATE DISCLOSURE											
	Transfers of Value re: Research & Development as defined – Article 18.5											2,400.00

Sweden

Data Disclosure Form													
Date of Publication: 30-06-2024													
HCPs	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country Identifier OPTIONAL	Donations and Grants to HCOs	Contribution to costs of Events			Fee for service and consultancy			Total Optional
							Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
								0	0	0	0		0
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
HCOs	Aggregate amount attributable to transfers of value to such Recipients							0	0	0	0		0
	Number of Recipients in aggregate disclosure							0	0	0	0		0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed							0	0	0	0		0
	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
						0	0	0	0	0	0		0
HCOs	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients					0	0	0	0	0	0		0
	Number of Recipients in aggregate disclosure					0	0	0	0	0	0		0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0	0	0	0	0	0		0
	AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined												42,000.00	

Switzerland

Data Disclosure Form												
Date of Publication: 30-06-2024												
HCPs	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique Country Identifier OPTIONAL	Donations and Grants to HCOs	Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	Total Optional
	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
								0	0	0	0	0
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients							0	144.71	2258.14	0	0
	Number of Recipients in aggregate disclosure							0	1	1	0	0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed							0	100%	100%	0	0
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)											
	Congrex Switzerland Ltd	Basel	Switzerland	Reinacherstrasse 131, 4053, Basel, Switzerland		0	15,000.00	0	0	0	0	15,000.00
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients					0	0	0	0	0	0	0
	Number of Recipients in aggregate disclosure					0	0	0	0	0	0	0
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed					0	0	0	0	0	0	0
AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined											0